Bristol Myers Squibb, Exelixis Get Priority Review for Kidney-Cancer Treatment
October 19 2020 - 7:48AM
Dow Jones News
By Matt Grossman
Bristol Myers Squibb Co. and Exelixis Inc. will get a priority
review on applications with the Food and Drug Administration for
combining Bristol's Opdivo and Exelixis's Cabometyx drugs to treat
kidney cancer, the companies said Monday.
In a recent Phase 3 trial, the combination showed significant
improvements in treating advanced renal-cell carcinoma compared
with sunitinib, another drug. The trial, which included 651
patients, showed that the Opdivo-Cabometyx combination was
associated with better health-related quality of life at most
intervals, Bristol and Exelixis said.
The FDA has given the companies' applications for the
combination treatment a target action date of Feb. 20.
In the U.S., Opdivo and Cabometyx have been approved on their
own to treat cancers.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 19, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024
